Nemucore Medical Innovations, Inc. Signs Letter of Intent with Xcellerex, Inc.

Online, April 18, 2012 (Newswire.com) - Nemucore Medical Innovations, Inc. (NMI) of Worcester, MA entered into a letter of intent with Xcellerex, Inc. (Xcellerex) of Marlborough, MA. Xcellerex manufactures the innovative modular platform, designated a FlexFactory®, to be deployed by NMI. Included in this single-use disposable system are controlled environmental modules, XDR bioreactors, and XDM mixing units, which together compose the core of a molecule agnostic manufacturing platform. This platform will be deployed in NMI's 11,000 sqft biomanufacturing space for the production of clinical grade nanomedicine for phase I and II clinical trials.

"The pharmaceutical industry is embracing a fundamental change in the biomanufacturing strategy used for new therapeutic agents," said Christopher McNary, Chief Commercial Officer, of Xcellerex.

"Single-use technologies and flexible manufacturing solutions, such as those pioneered by Xcellerex, are reducing time to clinic and minimizing capital investment and asset utilization risk. We are pleased to support companies such as NMI that are leading the way in developing exciting new biotherapies."

NMI CEO and President, Tim Coleman, said, "Xcellerex's innovative single use equipment will be essential in developing NMI as a national resource for nanomedicine biomanufacturing. Being able to provide access to quality and affordable manufacturing is a big step towards eliminating the present bottlenecks in manufacturing nanomedicines for transition to the clinic."

NMI expects to deploy the FlexFactory® systems in their Worcester facility sometime between the 4th Quarter of 2012 and 1st Quarter of 2013.

About Xcellerex Inc.
Xcellerex is commercializing turnkey biomanufacturing solutions that transform the speed and economics of producing therapeutic proteins, including biosimilars and vaccines. The company's FlexFactory® is a complete modular and portable production train based on single-use technologies, advanced process automation, and compact clean room architecture. FlexFactory allows deployment of GMP manufacturing capacity more rapidly and at greatly reduced costs compared with traditional facilities. Through its BridgeSourcing™ services, Xcellerex manufactures a partner's Biomolecules while the partner prepares for commissioning of its own new FlexFactory. When the partner's facility is ready, Xcellerex deploys its TransPlant™ process to install, validate, and train partner personnel in their own FlexFactory. This parallel-path model both accelerates time to clinical and commercial manufacturing and allows partners to manage the development and market risks associated with adding manufacturing capacity. Xcellerex also leverages its proprietary single-use technologies through the sale of XDR bioreactors, XDM Quad Mixers, and related single-use assemblies. To date, more than 20 therapeutic proteins and vaccines have been manufactured for clinical trials using Xcellerex technology. For more information please visit, www.xcellerex.com.